Pipeline victories accelerate Takeda despite brand pricing pressure
- Takeda is shifting its focus to New Launches to offset the loss of older drug revenue.
- ENTYVIO Pen has broad formulary access, but negative pricing mix is weighing on US sales.
- The late-stage pipeline is delivering, with ORZEYFUL launched in Japan and China, and MIMRYLO launched in the US.
- Clinical results for zasocitinib in ulcerative colitis showed a lack of dose response, complicating its expansion.
- Softening Albumin demand in China is a structural challenge driven by new government guidelines.
A cleaner handoff with new hurdles
Takeda is in the middle of a hard handoff. Older products are fading, led by VYVANSE after generic copies entered the market. At the same time, newer medicines are growing. Management is formally retiring the old Growth and Launch category to refocus the company purely on New Launches and Core In-line Brands. The headwind from VYVANSE generic erosion is steadily tapering off, and a major cost efficiency program has successfully offset the gross profit impact.
ENTYVIO is the key bridge. The Pen version now has access with all three large US pharmacy benefit managers, with more than 80 percent commercial coverage. That helps US growth stabilize after earlier payer access problems. However, the brand recently saw a US sales decline driven by a negative pricing mix, despite underlying demand growth.
The bull case rests on the pipeline, which has translated into concrete launch execution. ORZEYFUL is now launched in Japan and China for narcolepsy, though a missed listing window will delay the full commercial rollout in China until January 2028. MIMRYLO launched in the US for polycythemia vera in August with a favorable recommendation. Zasocitinib was accepted for priority review by the FDA for psoriasis.
New clinical risks have emerged. Zasocitinib recently failed to show a clean dose response in a Phase II ulcerative colitis trial, clouding the narrative for expanding the drug into inflammatory bowel disease. Open questions now center on the initial US commercial uptake metrics for the newest products and the duration of Albumin demand softening in China.
Patents fund the pipeline
Takeda makes money by selling prescription drugs, vaccines, and plasma-derived therapies. Many of its best products are protected by patents, special manufacturing know-how, or strong doctor use. When protection ends, generic or biosimilar rivals can take share and cut prices fast.
The company is trying to replace older revenue with a fresh wave of assets. The new focus is on products that are within five years of launch, ensuring the pipeline constantly refreshes the top line.
Cost cuts are a major part of the model right now. Management is using an enterprise-wide efficiency program and expects core operating profit margins to improve by 100 to 250 basis points annually from FY2025. A basis point is one one-hundredth of a percentage point.
There is a tradeoff. Takeda is cutting costs while preparing major launches. The company is actively executing on the upcoming launches of key late-stage pipeline assets. In its core Plasma-Derived Therapies business, Takeda is expanding its infrastructure through strategic partnerships, such as a collaboration with the Indonesian government to build plasma donation centers.
What carries the story
ENTYVIO
ENTYVIO treats inflammatory bowel disease. Its Pen version has broad US commercial coverage, reducing access risk, but negative pricing mix is pressuring sales.
VYVANSE
VYVANSE treats ADHD and is facing generic erosion. Takeda lost significant revenue here, but the worst pressure is tapering off.
Plasma-Derived Therapies
This business sells therapies made from human plasma. Subcutaneous immunoglobulin is growing well, but Albumin demand in China is challenged by new government guidelines.
QDENGA
QDENGA is a dengue vaccine. It is accelerating rapidly, driven primarily by demand in Brazil.
ORZEYFUL
ORZEYFUL is a narcolepsy type 1 drug. It launched in Japan and China, with a US launch pending scheduling.
MIMRYLO
MIMRYLO, also known as rusfertide, is aimed at polycythemia vera. Takeda launched it in the US with favorable clinical guidelines.
Zasocitinib
Zasocitinib is a psoriasis drug candidate under FDA priority review, though a lack of dose response in a recent trial complicates its expansion into other diseases.
Where revenue comes from
The mix uses fiscal year 2025 business-area revenue for the year ended March 31, 2026. Gastroenterology is the largest area.
What could break it
ENTYVIO competition and pricing
High impact · High oddsENTYVIO is central to the bridge from old drugs to new launches. The brand is seeing US sales contract under a negative pricing mix. Biosimilar rivals are an emerging risk in Europe.
Launch cycle execution
High impact · Medium oddsORZEYFUL, MIMRYLO, and zasocitinib carry a large part of the bull case. Regulatory hurdles can slow momentum, as seen with ORZEYFUL missing the China listing window.
Albumin softness in China
Medium impact · High oddsTakeda's plasma business is mixed. Albumin demand in China softened, driven by new government utilization guidelines. This is a longer-term structural headwind.
US pricing pressure
Medium impact · High oddsUS Medicare Part D redesign and 340B expansion create near-term gross-to-net pressure, meaning more rebates and discounts come off list prices.
Clinical expansion setbacks
Medium impact · Medium oddsClinical risk has emerged around zasocitinib's potential expansion into inflammatory bowel disease. A Phase II trial in ulcerative colitis failed to show a clean dose response.
In one breath
Why is Takeda stock tied to VYVANSE?
VYVANSE used to be a major profit source, but generic versions are taking share. The sharpest part of the erosion has passed.
What is Takeda's most important drug?
ENTYVIO is the key product to watch because it is large, still growing, and central to the transition plan. Future biosimilar competition is a major risk.
What are Takeda's next big launches?
The main late-stage launches are ORZEYFUL for narcolepsy, MIMRYLO for polycythemia vera, and zasocitinib for psoriasis. The first two are already launching in key markets.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - Specialty & Generic companies
Companies near Takeda Pharmaceutical Company Limited in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

